Table 2.
DMRs | Promoter | Gene body | Enhancer | CGIs | Open sea | |
---|---|---|---|---|---|---|
Immune cell subset-specific | DMRs | 16% versus 25% of total CpG sites (reduced) | 42% versus 33% of total CpG sites (enriched) | 75% versus 64% of total CpG sites (enriched) | 7% versus 31% of total CpG sites (reduced) | 55% versus 36% of total CpG sites (enriched) |
% DMGs of negatively correlated DEG-DMG pairs | 27% | 47% | ||||
% DMGs of positively correlated DEG-DMG pairs | 12% | 70% | ||||
Sex-specific | DMGs | 20% versus 25% of total CpG sites (reduced) | 36% versus 33% of total CpG sites (no change) | 60% versus 64% of total CpG sites (no change) | 38% versus 31% of total CpG sites (enriched) | 31% versus 36% of total CpG sites (reduced) |
Percentage of DMGs in a specific location, compared to the total CpG sites scanned by the chip in the location. We defined a difference ≥ 5% as enrichment or reduction.
Percentage of DMGs in the promoter or gene body out of correlated DEG-DMG pairs (other locations not included)